Decay of HIV Type 1 DNA and Development of Drug-Resistant Mutants in Patients with Primary HIV Type 1 Infection Receiving Highly Active Antiretroviral Therapy
- 20 November 2001
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 17 (17) , 1599-1604
- https://doi.org/10.1089/088922201753342004
Abstract
The present study was aimed at describing the effect of highly active antiretroviral therapy (HAART) in 10 patients with primary HIV infection (PHI). Clearance rates of HIV RNA and HIV DNA in peripheral blood as well as the preexistence and the emergence of drug-resistant strains of HIV were determined over 52 weeks of treatment. The data indicate that HAART is able to induce a suppression of plasma viral load together with a significant decrease, but not a suppression, of peripheral blood mononuclear cell-associated proviral DNA in PHI subjects. Analysis of drug-resistant strains revealed that three PHI patients, showing a complete virologic response, developed mutations in the pol gene, thus suggesting that a persistent residual virus replication exists despite a sustained suppression of plasma viremia.Keywords
This publication has 19 references indexed in Scilit:
- TT virus levels in the plasma of infected individuals with different hepatic and extrahepatic pathologyJournal of Medical Virology, 2001
- Biphasic Decay of Latently Infected CD4+T Cells in Acute Human Immunodeficiency Virus Type 1 InfectionThe Journal of Infectious Diseases, 2000
- The HIV Type 1 Protease Inhibitor Saquinavir Can Select for Multiple Mutations that Confer Increasing ResistanceAIDS Research and Human Retroviruses, 1999
- Early establishment of a pool of latently infected, resting CD4 + T cells during primary HIV-1 infectionProceedings of the National Academy of Sciences, 1998
- Severity and Prognosis of Acute Human Immunodeficiency Virus Type 1 Illness: A Dose‐Response RelationshipClinical Infectious Diseases, 1998
- Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection.The Journal of Infectious Diseases, 1997
- Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination TherapyScience, 1995
- Predictors of rapid progression to AIDS in HIV-1 seroconvertersAIDS, 1993
- Zidovudine in the management of primary HIV-1 infectionAIDS, 1991
- Clinical course of primary HIV infection: consequences for subsequent course of infection.BMJ, 1989